RxDoctor Payments Data

Kwasi Dakwa, MD

Interventional Cardiology · Bridgeport, CTNPI 1861788382

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.6%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Philips North America LLC at 38.1% of the total. 2025 is the largest year on record at $1,092, 2.1 times the $517 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.

$2,691in general payments, 2019–2025

Across 34 payments — averaging $79.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$1K
  • Abiomed$708
  • GE HealthCare$210
  • Shockwave Medical, Inc$144
  • Edwards Lifesciences$125
  • Abbott$122
  • plus $356 from 7 others

What the payments were for

  • Grants$271%
  • Travel & lodging$1,19544%
  • Food & beverage$1,46955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,691 in reported general payments places this provider in the 30th percentile of 73 interventional cardiology providers in Connecticut.

See all interventional cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$100,615
Medicare patients
1,068
Services billed
2,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$164,057
BrilintaTicagrelor72$58,628
JardianceEmpagliflozin24$26,666
XareltoRivaroxaban15$21,644
Repatha SureclickEvolocumab18$17,029
Metoprolol Succinate359$6,548
Rosuvastatin Calcium236$3,268
ClopidogrelClopidogrel Bisulfate200$2,796
Atorvastatin Calcium162$2,215
Diltiazem 24hr Er (Cd)Diltiazem Hcl67$1,754
Potassium Chloride47$1,503
Losartan Potassium151$1,386
Furosemide117$955
Bumetanide30$857
Spironolactone81$818

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →